US prevalence
~30M US adults
Source: AASM
ConditionICD-10: G47.33
Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a sleep disorder where breathing repeatedly stops and starts because the airway collapses during sleep. It affects an estimated 30 million US adults, contributes to cardiovascular disease, daytime fatigue, and reduced quality of life — and is closely linked to obesity, with weight loss often dramatically improving symptoms. The FDA approved Zepbound (tirzepatide) in December 2024 specifically for moderate-to-severe OSA in adults with obesity, making it the first GLP-1 with this on-label indication.
Quick answer
UpdatedObstructive sleep apnea (OSA) is a sleep disorder where airway collapses during sleep, causing repeated breathing pauses. Estimated 30 million US adults have OSA (many undiagnosed). Obesity is the strongest modifiable risk factor. In 2024, FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity — first GLP-1 with this specific indication. SURMOUNT-OSA trial: 51% improvement in apnea events at 52 weeks.
- US prevalence: ~30 million adults
- AASM data; many undiagnosed
- Obesity link: 70% of OSA patients have obesity
- Each 10% weight gain → 6× higher OSA risk
- Zepbound efficacy: 51% improvement in apnea events
- SURMOUNT-OSA trial, 52 weeks (FDA-approved 2024)
- CPAP-discontinuation: Possible after 10-15% weight loss
- Sleep retest after weight loss often shows OSA resolution
- First-line therapy: CPAP (continuous positive airway pressure)
- Weight loss + GLP-1 are adjuncts or replacements
Last clinical review
By GLP1Zoom editorial board
GLP-1 role
Zepbound FDA-approved for moderate-to-severe OSA in obese adults (2024). Other GLP-1s used off-label for weight loss in OSA patients.
Key takeaways
- • Zepbound is the FIRST and ONLY FDA-approved drug for OSA (Dec 2024).
- • Approved only for moderate-to-severe OSA in adults with obesity.
- • AHI reductions of 25-30 events/hour in the SURMOUNT-OSA trials.
- • Does not replace CPAP for all patients — discuss with sleep medicine.
- • Some commercial plans have updated OSA coverage; verify with your formulary.
Key facts
- •~30 million US adults have OSA; 80%+ are undiagnosed (American Academy of Sleep Medicine)
- •OSA prevalence is 2-4x higher in adults with obesity (BMI ≥30)
- •Zepbound (tirzepatide) FDA-approved Dec 2024 for moderate-severe OSA + obesity
- •In the SURMOUNT-OSA trial, tirzepatide reduced apnea-hypopnea index (AHI) by ~25-29 events/hour
- •Weight loss of 10% can reduce OSA severity by 30-50% even without medication
- •OSA increases risk of stroke, heart attack, atrial fibrillation, and type 2 diabetes
Why GLP-1 medications
OSA pathophysiology is driven significantly by excess soft tissue in upper airway and around the pharynx — both reduced by weight loss. GLP-1 medications produce 15-22% body-weight reduction, which directly decompresses the airway and reduces apnea events. The SURMOUNT-OSA trials (published 2024 NEJM) showed tirzepatide reduced AHI by ~25-29 events/hour at 52 weeks, with 43% of patients reaching the threshold for OSA resolution. Beyond the direct airway effect, GLP-1 also improves the metabolic profile (insulin resistance, inflammation) that worsens OSA outcomes.
GLP-1 drugs prescribed for Obstructive Sleep Apnea
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Zepbound$349–$1086/mo
tirzepatide
98/100 matchFDA-approved (Dec 2024) for moderate-to-severe OSA in adults with obesity — only GLP-1 with on-label OSA indication
Compare providers - Mounjaro$1023–$1330/mo
tirzepatide
80/100 matchSame molecule as Zepbound (tirzepatide) — used off-label for OSA when Zepbound unavailable
Compare providers - Wegovy$1349–$1500/mo
semaglutide
70/100 matchOff-label for OSA — weight loss reduces apnea events; no specific OSA indication
Compare providers - Compounded Tirzepatide$149–$399/mo
tirzepatide (compounded)
60/100 matchOff-label compounded — weight loss may improve OSA; regulatory uncertainty applies
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Zepbound tirzepatide | $349–$1086/mo | 98/100 | FDA-approved (Dec 2024) for moderate-to-severe OSA in adults with obesity — only GLP-1 with on-label OSA indication | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 80/100 | Same molecule as Zepbound (tirzepatide) — used off-label for OSA when Zepbound unavailable | Compare |
| Wegovy semaglutide | $1349–$1500/mo | 70/100 | Off-label for OSA — weight loss reduces apnea events; no specific OSA indication | Compare |
| Compounded Tirzepatide tirzepatide (compounded) | $149–$399/mo | 60/100 | Off-label compounded — weight loss may improve OSA; regulatory uncertainty applies | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Common symptoms
- Loud, chronic snoring (often noted by a bed partner)
- Gasping or choking awakenings during sleep
- Witnessed pauses in breathing during sleep
- Excessive daytime sleepiness despite adequate sleep duration
- Morning headache, dry mouth, or sore throat
- Difficulty concentrating, irritability, or mood changes
- Nocturia (waking multiple times to urinate)
- High blood pressure, particularly if difficult to control
How obstructive sleep apnea is diagnosed
Diagnosis requires an overnight sleep study (polysomnography in a sleep lab, or home sleep apnea test for selected patients). The Apnea-Hypopnea Index (AHI) — number of breathing interruptions per hour — categorizes severity: mild (5-14), moderate (15-29), severe (≥30). The STOP-BANG questionnaire is a common screening tool used in primary care to identify candidates for sleep testing. Untreated OSA is associated with substantially increased cardiovascular risk.
Treatment options
CPAP / BiPAP (gold standard)
Continuous Positive Airway Pressure delivered via mask during sleep keeps airway open. Highly effective when used; adherence is the main limitation (many patients can't tolerate the mask long-term).
GLP-1 medications (newer option)
Zepbound FDA-approved for moderate-severe OSA + obesity (Dec 2024). Reduces AHI through weight loss + direct airway effects. Now insurance-covered for this indication in many plans.
Oral appliances
Dental mandibular advancement devices reposition the jaw to keep airway open. Best for mild-moderate OSA or CPAP-intolerant patients.
Surgery
Uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement, or hypoglossal nerve stimulator (Inspire). Reserved for select anatomical cases.
Bariatric surgery
For severe obesity (BMI ≥35), bariatric surgery often resolves OSA entirely along with weight loss. Pre- and post-op sleep studies typically required.
Positional therapy
Side-sleeping devices for patients whose OSA is positional (worse when supine). Adjunct, not standalone treatment.
Compare telehealth providers for Obstructive Sleep Apnea
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Ro· from $145/moHighest score in our rubricTelehealth · Obstructive Sleep Apnea care
- Hers· from $99/moFDA-approved brand medicationTelehealth · Obstructive Sleep Apnea care
- Hims· from $99/moNo video visit requiredTelehealth · Obstructive Sleep Apnea care
- LifeMD· from $89/moBills your insuranceTelehealth · Obstructive Sleep Apnea care
Lifestyle & self-care
- Weight loss — even 5-10% body weight reduction substantially improves AHI
- Avoid alcohol within 3 hours of bedtime — alcohol relaxes airway muscles, worsens OSA
- Sleep on side (not back) — supine sleep increases airway collapse
- Treat nasal congestion — chronic congestion worsens OSA
- Maintain regular sleep schedule — sleep deprivation worsens OSA severity
- Stop smoking — increases upper airway inflammation and apnea events
When to see a doctor
Make an appointment if you have:
- →Loud snoring noticed by a bed partner, especially with witnessed apneas
- →Excessive daytime sleepiness affecting work, driving, or quality of life
- →High blood pressure that's difficult to control
- →Morning headaches and dry mouth on waking
- →BMI ≥30 with sleep complaints (much higher OSA risk)
- →Heart disease, atrial fibrillation, or stroke history (OSA screening recommended)
Medications for Obstructive Sleep Apnea
Wegovy
semaglutide
GLP1Zoom score: 8.9/10
From $1349/mo
Zepbound
tirzepatide
GLP1Zoom score: 9.3/10
From $349/mo
Mounjaro
tirzepatide
GLP1Zoom score: 6.6/10
From $1023/mo
Compounded Tirzepatide
tirzepatide (compounded)
GLP1Zoom score: 6.5/10
From $149/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizObstructive Sleep Apnea& GLP-1 — frequently asked questions
Can GLP-1 medications treat Obstructive Sleep Apnea?
OSA pathophysiology is driven significantly by excess soft tissue in upper airway and around the pharynx — both reduced by weight loss. GLP-1 medications produce 15-22% body-weight reduction, which directly decompresses the airway and reduces apnea events. The SURMOUNT-OSA trials (published 2024 NEJM) showed tirzepa…
Which GLP-1 medications are used for Obstructive Sleep Apnea?
GLP-1 options associated with Obstructive Sleep Apnea include Zepbound, Mounjaro, Wegovy, Compounded Tirzepatide. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for Obstructive Sleep Apnea?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for Obstructive Sleep Apnea or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
Sources
- American Academy of Sleep Medicine — OSA Facts
- SURMOUNT-OSA Trial (NEJM 2024) — Tirzepatide for OSA
- FDA Approval of Zepbound for OSA (Dec 2024)
- CDC — Sleep and Sleep Disorders
Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
How Obstructive sleep apnea is diagnosed
Who diagnoses: Primary care provider, sleep medicine specialist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
STOP-BANG screening
8-question validated screening (snoring, tired, observed apnea, BP, BMI, age, neck circumference, sex)
Threshold: Score ≥3 = intermediate risk; ≥5 = high risk
- 2
Sleep study (polysomnography)
In-lab overnight study OR home sleep apnea test
Threshold: AHI ≥5 = OSA; ≥15 = moderate; ≥30 = severe
- 3
Severity grading
Apnea-Hypopnea Index (AHI) + oxygen desaturation pattern + symptom burden
- 4
Treatment planning
CPAP for moderate-severe; oral appliance for mild-moderate; consider weight loss + Zepbound for OSA + obesity
Threshold: BMI ≥30 + AHI ≥15 = Zepbound-eligible per FDA 2024
- 5
Follow-up + adherence
CPAP compliance check at 1-3 months; weight + AHI reassessment with weight loss
Source: AASM Clinical Practice Guidelines
Treatment decision criteria
When does a GLP-1 fit Obstructive Sleep Apnea?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- Zepbound specifically FDA-approved for moderate-to-severe OSA in adults with obesity
- CPAP-intolerant patient with obesity
- Patient seeking CPAP-reduction or discontinuation pathway via weight loss
- Concurrent T2D or CVD risk
Try alternatives first if…
- Mild OSA without obesity — CPAP first
- Newly diagnosed — CPAP trial usually first
- Anatomic-driven OSA (surgical candidate) — ENT evaluation
- Positional sleep apnea — positional therapy may suffice
First-line alternatives for Obstructive Sleep Apnea
- CPAP
- Gold standard; immediate symptom resolution
- Oral appliance
- For mild-moderate OSA or CPAP-intolerant
- Weight loss (lifestyle)
- 10-15% weight loss often resolves OSA
- Surgical intervention
- For anatomic causes (UPPP, tonsillectomy, maxillomandibular)
Authoritative sources on Obstructive Sleep Apnea
- Sleep apnea — NIH — NHLBI